David Pasquier

Full Professor Radiation Oncology, MD PhD, Academic Department of Radiation Oncology, Centre Oscar Lambret, Lille University, CRIStAL UMR 9189

[ASTRO @ASTRO_org]

New in #practicalRO: MRI-based Atlas for Prostate Bed Recurrence after Radical Prostatectomy: Consistency of CTV Delineation with 7 Contouring Guidelines. https://t.co/YgnIU9w5Ns

[David Pasquier @David__Pasquier]

https://t.co/z5nCqhFCsx

[The Lancet Oncology @TheLancetOncol]

🔴Online now: Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised #prostatecancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial

https://t.co/x5xngvO2qP

[NEJM @NEJM]

Our latest video in our partnership with @DGlaucomflecken summarizes the final analysis of 23 years of follow-up to evaluate the long-term effects of PSA screening. Read the full analysis for free: https://t.co/QsGtl1BnFT

[Adela @adelapoite]

ASTRO Experts Comment on the Results of the SUPREMO Trial - The ASCO Post https://t.co/oJZpx8B6ua

[David Pasquier @David__Pasquier]

@MarionTonneau @GETUG_Unicancer @UFR3S_ULille

[David Pasquier @David__Pasquier]

Delighted to share the publication of the Dummy Run for the GETUG 31 trial, on salvage stereotactic re-irradiation of the prostate

→ Significant (and expected!) variability in GTV and urethra delineation
→ Multiparametric prescription for harmonization
https://t.co/7TZtofFxvv

[David Pasquier @David__Pasquier]

Congratulations @MarionTonneau
@GETUG_Unicancer @UFR3S_ULille @ Centre Oscar Lambret

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Just in from #ESMO25 Berlin👉Phase III PSMAAddition trial shows that adding ¹⁷⁷Lu-PSMA-617 to ADT + ARPI significantly improved rPFS (HR 0.72; p = 0.002) in PSMA-positive mHSPC, with consistent benefit across subgroups. OS immature.
#ProstateCancer @OncoAlert @UroToday

[Melvin LK CHUA | FRCR, PhD, FASCO @DrMLChua]

#ESMO25

Highly anticipated results of ENZARAD

The results speak for themselves but I think this is something @DrSpratticus has been harping about for blanket ARSI for high risk #ProstateCancer patients

[David Pasquier @David__Pasquier]

Impressive long term results!

[UroToday.com @urotoday]

Single-dose carboplatin and involved-node radiotherapy for seminoma stage IIA/B: Long-term follow-up from the international multicenter phase II trial SAKK 01/10. Presentation by @Alex_Papachris. #ESMO25 written coverage by @chavarriagaj > https://t.co/98mM0TN5Zd @myESMO

[UroToday.com @urotoday]

Single-dose carboplatin and involved-node radiotherapy for seminoma stage IIA/B: Long-term follow-up from the international multicenter phase II trial SAKK 01/10. Presentation by @Alex_Papachris. #ESMO25 written coverage by @chavarriagaj > https://t.co/98mM0TN5Zd @myESMO

[David Pasquier @David__Pasquier]

@CACancerJournal @OncoAlert Delighted to have contributed!

[Drew Moghanaki @DrewMoghanaki]

An intriguing poster at #ASTRO25 demonstrates that major North American TV Shows are leading viewers to believe radiation might cause "internal melting, burning, or crumbling, or even a food allergy". @ASTRO_org @PRJeffWhite @NehaVapiwala @sueyom https://t.co/r6yOOgQrJ0

[Dr. Andrew Loblaw @DrAndrewLoblaw]

@jamesbyu #GU005
SBRT had better QOL vs MHF (20-28fx) in:
1 year: sexual and bowel
2 years: urinary irritation
Spacers / balloons didn't influence outcomes

[David Pasquier @David__Pasquier]

@5_utr Thks!

[Accuray en français @Accuray_Fr]

Intéressé par une comparaison des logiciels de contourage automatique des #CancerDuSein & #CancerDeLaProstate dans les centres de #radiothérapie des Hauts de France ? Venez lire le poster PO03_018 du Prof. @David__Pasquier (Centre Oscar Lambret) #CongresSFRO2025 #RadOnc @sfro_fr